David A. Siegel Amicus Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 345,376 shares of FOLD stock, worth $3.27 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
345,376
Previous 896,576
61.48%
Holding current value
$3.27 Million
Previous $5.14 Million
47.03%
% of portfolio
0.01%
Previous 0.01%
Shares
26 transactions
Others Institutions Holding FOLD
# of Institutions
323Shares Held
323MCall Options Held
1.09MPut Options Held
1.04M-
Vanguard Group Inc Valley Forge, PA29.5MShares$280 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA28.6MShares$271 Million0.04% of portfolio
-
Black Rock Inc. New York, NY24.4MShares$231 Million0.01% of portfolio
-
William Blair Investment Management, LLC Chicago, IL15.7MShares$149 Million0.35% of portfolio
-
Avoro Capital Advisors LLC New York, NY15MShares$142 Million1.62% of portfolio
About AMICUS THERAPEUTICS, INC.
- Ticker FOLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 280,497,984
- Market Cap $2.66B
- Description
- Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...